lifestyle.clientim.com

Author: Aptevo Therapeutics

Aptevo Therapeutics Provides a 1Q26 Business Update; RAINIER on Track for 2026 Completion and Phase 2 Dose Selection

May 13, 2026
Aptevo Reports 87% Clinical Benefit and 81% Remission in 31 Evaluable Frontline AML Patients Through Cohort 5, Substantially Outperforming Benchmark; RAINIER on Track for 2026 Completion and Phase 2 Dose Selection

May 6, 2026
Aptevo Provides State of the Business Report and 2025 Financial Results

March 26, 2026
Aptevo to Participate in March 2026 Conferences

March 19, 2026
Mipletamig Delivers Compelling 86% Clinical Benefit Rate and No CRS as Evaluable AML Patient Data increases by Nearly 50%

March 10, 2026
Aptevo Announces Executive Leadership Transitions to Support Next Phase of Growth

February 3, 2026
Aptevo Therapeutics Secures $60 Million Equity Line of Credit to Support Multispecific Portfolio Advancement, Increase Strategic Optionality

January 9, 2026
Aptevo Therapeutics Announces 1-for-18 Reverse Stock Split

December 26, 2025
Aptevo Therapeutics Highlights Compelling Safety and Strong Remission Rates for Mipletamig in Frontline AML at ASH 2025

December 9, 2025